The Evolution of HIV Treatment: Patients Journey to Understanding Available Treatment Options to Overcome Barriers to Care

View Activity

FACULTY

David Michael Asmuth, MD
Professor
Division of Infectious Diseases
Department of Internal Medicine
UC Davis Medical Center
Sacramento, CA

PROGRAM OVERVIEW

This online activity is focused on the team involved in the management of patients with HIV.

TARGET AUDIENCE

This activity is intended for U.S.-based primary care providers involved in the management of patients living with HIV infection, such as internists, family physicians, physician assistants, and nurse practitioners.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Describe the clinical and economic burdens of long-term HIV infection
  • Integrate evidence-based diagnostic and therapeutic recommendations for people living with HIV infection into clinical practice
  • Discuss efficacy and safety data from recent clinical trials on new and emerging agents for patients living with HIV
  • Employ effective patient/provider communication to promote retention in the continuum of care and ART adherence for those living with long-term HIV infection

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with HIV. Credits: 1.0 ANCC Contact Hours.

CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

David Michael Asmuth, MD, is on the speakers’ bureau for Merck ViiV (GSK), Janssen and Gilead. He is on the Advisory Board for ViiV (GSK) and Gilead. He is on the Scientific Advisory Board for Napo Pharmaceuticals. Dr. Asmuth receives research grants for ViiV (GSK).

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group, has nothing to disclose.
Nina Oshiokpekhai MS, PharmD of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

RELEASE DATE: October 1, 2018

EXPIRATION DATE: October 1, 2019

View Activity

Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.